Johnson & Johnson logo

Johnson & Johnson (JNJ)

Market Open
16 Dec, 17:25
NYSE NYSE
$
209. 93
-4.24
-1.98%
$
500.07B Market Cap
29.06 P/E Ratio
4.96% Div Yield
173,161 Volume
9.91 Eps
$ 214.17
Previous Close
Day Range
209.82 214.73
Year Range
140.68 215.19
Want to track JNJ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 36 days
Cancer victims file class action against Johnson & Johnson over ‘fraudulent' bankruptcies

Cancer victims file class action against Johnson & Johnson over ‘fraudulent' bankruptcies

A group of cancer victims sued Johnson & Johnson JNJ.N on Wednesday, accusing the healthcare company of committing fraud through repeated and continued efforts to use a shell company's bankruptcy to resolve tens of thousands of lawsuits alleging its talc products contained asbestos and caused cancer.

Nypost | 1 year ago
Cancer victims sue Johnson & Johnson over 'fraudulent' bankruptcies

Cancer victims sue Johnson & Johnson over 'fraudulent' bankruptcies

A group of cancer victims sued Johnson & Johnson on Wednesday, accusing the healthcare company of committing fraud through repeated and continued efforts to use a shell company's bankruptcy to resolve tens of thousands of lawsuits alleging its talc products contained asbestos and caused cancer.

Reuters | 1 year ago
7 Safe-Haven Stocks to Weather Any Storm

7 Safe-Haven Stocks to Weather Any Storm

Investors often look to safe-haven equities for stability and reliable returns during uncertain economic times. Here are seven strong afe-haven stocks to buy that offer encouraging chances to endure financial disasters.

Investorplace | 1 year ago
Want $1,000 in Dividend Income? Here's How Much You'd Have to Invest in Johnson & Johnson Stock

Want $1,000 in Dividend Income? Here's How Much You'd Have to Invest in Johnson & Johnson Stock

Johnson & Johnson's dividend currently yields more than 3%. The healthcare giant has increased its payout every year for more than half a century.

Fool | 1 year ago
J&J-backed startup Rapport files for US IPO

J&J-backed startup Rapport files for US IPO

Biopharmaceutical company Rapport Therapeutics, backed by the venture capital arm of Johnson & Johnson , filed for an initial public offering in the United States on Friday.

Reuters | 1 year ago
J&J (JNJ) to Boost Dermatology Portfolio With New Acquisition

J&J (JNJ) to Boost Dermatology Portfolio With New Acquisition

Johnson & Johnson (JNJ) inks deal to acquire Proteologix, Inc. for $850 million in cash. The transaction is expected to be closed in mid-2024.

Zacks | 1 year ago
Johnson & Johnson (JNJ) Up 5.5% Since Last Earnings Report: Can It Continue?

Johnson & Johnson (JNJ) Up 5.5% Since Last Earnings Report: Can It Continue?

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 year ago